Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Our Chief Data Officer, Derrick Lichti, is one of the featured speakers, alongside Reid McEachran of Ardent Mills and hosted by Tricia Ryan of BAC
3.2 GLP-1RAs in psoriatic arthritis The therapeutic landscape of PsA is currently dominated by targeted agents that inhibit key inflammatory pathways, including TNF inhibitors (e.g., adalimumab, etanercept), IL17 inhibitors (e.g., secukinumab, ixekizumab), IL-23 inhibitors (e.g., guselkumab, risankizumab), and Janus kinase (JAK) inhibitors such as upadacitinib and tofacitinib (62)
Research Use Only Our products are intended exclusively for use in laboratories, universities, and by qualified independent researchers
Insurance barriers: While some insurance plans cover GLP-1 therapies, navigating the processes of step therapy and prior authorization can be overwhelming for patients
US$ 27.49
US$ 28.28
US$ 24.78
US$ 24.07
US$ 20.69
US$ 25.03
US$ 21.20
US$ 23.49
US$ 20.99
US$ 25.77
US$ 28.05
US$ 22.24
